Edition:
United States

Prothena Corporation PLC (PRTA.OQ)

PRTA.OQ on NASDAQ Stock Exchange Global Select Market

33.20USD
16 Feb 2018
Change (% chg)

$1.09 (+3.39%)
Prev Close
$32.11
Open
$31.81
Day's High
$34.41
Day's Low
$31.80
Volume
161,413
Avg. Vol
155,265
52-wk High
$70.00
52-wk Low
$27.19

Latest Key Developments (Source: Significant Developments)

Prothena Q4 Loss Per Share $1.24
Wednesday, 14 Feb 2018 04:05pm EST 

Feb 14 (Reuters) - Prothena Corporation Plc ::PROTHENA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS, AND PROVIDES FINANCIAL GUIDANCE AND RESEARCH AND DEVELOPMENT UPDATE.Q4 LOSS PER SHARE $1.24.Q4 REVENUE $200,000.AS OF DECEMBER 31, 2017, PROTHENA HAD $421.7 MILLION IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH AND NO DEBT.EXPECTS THE FULL YEAR 2018 NET CASH BURN FROM OPERATING AND INVESTING ACTIVITIES TO BE $175 TO $230 MILLION.Q4 EARNINGS PER SHARE VIEW $-1.48, REVENUE VIEW $237600.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Prothena reports Q3 loss per share $1.37
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Prothena Corporation Plc ::Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports third quarter financial results
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Prothena Corporation Plc :Prothena reports third quarter 2017 financial results and provides research and development update.Q3 loss per share $1.37.Q3 revenue $200,000.Q3 revenue view $251,000 -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports Q2 loss per share $0.46
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 9 (Reuters) - Prothena Corporation Plc -:Prothena reports second quarter 2017 financial results and provides research and development update.Q2 loss per share $0.46.Q2 revenue $26.8 million.Q2 revenue view $15.1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.88 -- Thomson Reuters I/B/E/S.Prothena Corporation Plc - ‍as of june 30, 2017, prothena had $475.8 million in cash, cash equivalents and restricted cash and no debt.​.Prothena Corporation Plc - ‍expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million​.  Full Article

Prothena Q2 loss per share $0.46
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Prothena Corporation Plc :Prothena reports second quarter 2017 financial results and provides research and development update.Q2 loss per share $0.46.Q2 revenue $26.8 million.Q2 revenue view $15.1 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.88 -- Thomson Reuters I/B/E/S.Prothena Corporation PLC says we expect topline results from phase 1B mad study of PRX003 in patients with psoriasis in october.Prothena Corporation PLC says expect topline results from phase 2b pronto study of neod001 in patients with al amyloidosis in q2 of 2018.  Full Article

Prothena reports Q1 2017 financial results
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Prothena Corporation PLC ::Prothena Corporation PLC says expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million.Reports first quarter 2017 financial results and provides research and development update.Q1 loss per share $0.99.Q1 revenue $300,000 versus i/b/e/s view $261,000.Q1 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.  Full Article

Prothena reports Q1 loss per share $0.99
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Prothena Corporation Plc :Prothena reports first quarter 2017 financial results and provides research and development update.Q1 loss per share $0.99.Q1 revenue $300,000 versus I/B/E/S view $261,000.Q1 earnings per share view $-1.39 -- Thomson Reuters I/B/E/S.Prothena Corporation Plc - company expects full year 2017 net cash burn from operating and investing activities to be $160 to $170 million.  Full Article

Prothena Corp, Prothena Biosciences enter letter agreement with Boehringer Ingelheim
Wednesday, 12 Apr 2017 06:48am EDT 

Prothena Corporation Plc : Prothena Corporation - on April 5, 2017, co and Prothena Biosciences entered letter agreement with Boehringer Ingelheim Biopharmaceuticals GMBH . Prothena Corp - Boehringer Ingelheim reserved for Prothena capacity to manufacture and supply bulk drug substance of NEOD001, PRX003, possibly additional biologics .Prothena Corp - under agreement, Prothena made commitments for purchase of products from Boehringer Ingelheim.  Full Article

Prothena announces pricing of public offering of 2,700,000 ordinary shares
Friday, 3 Mar 2017 08:30am EST 

Prothena Corporation Plc :Prothena announces pricing of public offering of 2,700,000 ordinary shares.  Full Article

Prothena announces pricing of public offering of 2,700,000 ordinary shares
Friday, 3 Mar 2017 08:30am EST 

Prothena Corporation Plc : Prothena announces pricing of public offering of 2,700,000 ordinary shares .Prothena Corporation Plc - has sold 2.7 million of its ordinary shares at a price to public of $57.50 per ordinary share.  Full Article